{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "Amount",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P01563",
      "entity_text" : "interferon-alpha2",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false,
    "context" : {
      "TissueType" : [ "tissuelist:TS-0923" ],
      "Species" : [ "taxonomy:76720" ]
    }
  },
  "verbose_text" : "In addition, for the ADA positive but not ADA negative patients, the serum levels of interferon-alpha2 (IFN-alpha2) and B-cell activating factor (BAFF) were significantly increased after the initiation of IFX treatment, whereas the serum interleukin-6 (IL-6) and IFN-gamma levels remained high levels.",
  "reading_complete" : "2020-08-08T15:34:33Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-08T15:30:58Z",
  "trigger" : "levels",
  "evidence" : [ "levels of interferon-alpha2" ],
  "pmc_id" : "5028026",
  "score" : 0
}